<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7905840</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6445</journal-id>
<journal-id journal-id-type="nlm-ta">Pharmacol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Ther.</journal-id>
<journal-title-group>
<journal-title>Pharmacology &amp; therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0163-7258</issn>
<issn pub-type="epub">1879-016X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28723414</article-id>
<article-id pub-id-type="pmc">5743581</article-id>
<article-id pub-id-type="doi">10.1016/j.pharmthera.2017.07.007</article-id>
<article-id pub-id-type="manuscript">NIHMS897832</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Omega-3 Polyunsaturated Fatty Acids as a Treatment Strategy for Nonalcoholic Fatty Liver Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jump</surname>
<given-names>Donald B.</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lytle</surname>
<given-names>Kelli A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Depner</surname>
<given-names>Christopher M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tripathy</surname>
<given-names>Sasmita</given-names>
</name>
</contrib>
<aff id="A1">Molecular Nutrition and Diabetes Research Laboratory, School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, 97331</aff>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding Author: Donald B. Jump, Ph.D., Molecular Nutrition &amp; Diabetes Research Lab, School of Biological and Population Health Sciences, 107A Milam Hall, Oregon State University, Corvallis, Oregon, 97331, Tel.: 541-737-4007, <email>Donald.Jump@oregonstate.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>10. Conflict of interest statement.</bold>
</p>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>4</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>181</volume>
<fpage>108</fpage>
<lpage>125</lpage>
<!--elocation-id from pubmed: 10.1016/j.pharmthera.2017.07.007-->
<abstract>
<p id="P2">Obese and type 2 diabetic (<bold>T2DM</bold>) patients have a high prevalence of nonalcoholic fatty liver disease (<bold>NAFLD</bold>). NAFLD is a continuum of chronic liver diseases ranging from benign hepatosteatosis to nonalcoholic steatohepatitis (<bold>NASH</bold>), cirrhosis and primary hepatocellular cancer (<bold>HCC</bold>). Because of its strong association with the obesity epidemic, NAFLD is rapidly becoming a major public health concern worldwide. Surprisingly, there are no FDA approved NAFLD therapies; and current therapies focus on the co-morbidities associated with NAFLD, namely, obesity, hyperglycemia, dyslipidemia, and hypertension. The goal of this review is to provide background on the disease process, discuss human studies and preclinical models that have examined treatment options. We also provide an in-depth rationale for the use of dietary ω3 polyunsaturated fatty acid (<bold>ω3 PUFA</bold>) supplements as a treatment option for NAFLD. This focus is based on recent studies indicating that NASH patients and preclinical mouse models of NASH have low levels of hepatic C<sub>20-22</sub> ω3 PUFA. This decline in hepatic PUFA may account for the major phenotypic features associated with NASH, including steatosis, inflammation and fibrosis. Finally, our discussion will address the strengths and limitations of ω3 PUFA supplements use in NAFLD therapy.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>